Tissue and plasma proteomics for early stage cancer detection-Reference-Cited by-同舟云学术

Tissue and plasma proteomics for early stage cancer detection

Published:2018 Issue:6 Volume:14 Page:405-423
ISSN:2515-4184
Container-title:Molecular Omics
language:en
Short-container-title:Mol. Omics

Author:

Peng Liyuan¹²³,Cantor David I.⁴⁵⁶^ORCID,Huang Canhua¹²³,Wang Kui¹²³,Baker Mark S.⁷⁶^ORCID,Nice Edouard C.⁸⁹⁶^ORCID

Affiliation:

1. Dept of Biotherapy, State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, and West China School of Basic Medical Sciences & Forensic Medicine, Sichuan University, and Collaborative Innovation Center for Biotherapy

2. Chengdu

3. P. R. China

4. Australian Proteome Analysis Facility (APAF), Department of Molecular Sciences, Macquarie University

5. New South Wales

6. Australia

7. Department of Biomedical Sciences, Faculty of Medicine & Health Sciences, Macquarie University

8. Department of Biochemistry and Molecular Biology, Monash University

9. Clayton

Abstract

The pursuit of novel and effective biomarkers is essential in the struggle against cancer, which is a leading cause of mortality worldwide. Here we discuss the relative advantages and disadvantages of the most frequently used proteomics techniques, concentrating on the latest advances and application of tissue and plasma proteomics for novel cancer biomarker discovery.

Funder

National Natural Science Foundation of China

Department of Science and Technology of Sichuan Province

Publisher

Royal Society of Chemistry (RSC)

Subject

Genetics,Molecular Biology,Biochemistry

Link

http://pubs.rsc.org/en/content/articlepdf/2018/MO/C8MO00126J

Reference147 articles.

1. Global, Regional, and National Cancer Incidence, Mortality, Years of Life Lost, Years Lived With Disability, and Disability-Adjusted Life-years for 32 Cancer Groups, 1990 to 2015

2. Global cancer statistics, 2012